Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study

The Lancet

Volumn 388, Issue 10056, 2016, Pages 2142-2152

  Vidal Petiot, Emmanuelle ^a,b,j   Ford, Ian ^c   Greenlaw, Nicola ^c   Ferrari, Roberto ^d,e   Fox, Kim M ^f   Tardif, Jean Claude ^g   Tendera, Michal ^h   Tavazzi, Luigi ^d   Bhatt, Deepak L ⁱ   Steg, Philippe Gabriel ^a,b,f,k  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d MARIA CECILIA HOSPITAL   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g MONTREAL HEART INSTITUTE   (Canada)

^h MEDICAL UNIVERSITY OF SILESIA   (Poland)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^k Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIASTOLIC BLOOD PRESSURE; DISEASE REGISTRY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; HYPOTENSION; MORTALITY; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; HYPOTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

EID: 84994171988     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31326-5     Document Type: Article

References (31)

1. 1 Zanchetti, A, Thomopoulos, C, Parati, G, Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 116 (2015), 1058–1073.
2. 2 Ettehad, D, Emdin, CA, Kiran, A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
3. 3 Kjeldsen, SE, Lund-Johansen, P, Nilsson, PM, Mancia, G, Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension 67 (2016), 808–812.
4. 4 Jones, DW, Weatherly, L, Hall, JE, SPRINT: what remains unanswered and where do we go from here?. Hypertension 67 (2016), 261–262.
5. 5 Mancia, G, Grassi, G, Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 63 (2014), 29–36.
6. 6 Verdecchia, P, Angeli, F, Mazzotta, G, Garofoli, M, Reboldi, G, Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement. Hypertension 63 (2014), 37–40.
7. 7 Cushman, WC, Evans, GW, Byington, RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
8. 8 Benavente, OR, Coffey, CS, Conwit, R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382 (2013), 507–515.
9. 9 Cruickshank, JM, Thorp, JM, Zacharias, FJ, Benefits and potential harm of lowering high blood pressure. Lancet 1 (1987), 581–584.
10. 10 Messerli, FH, Mancia, G, Conti, CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006), 884–893.
11. 11 Sleight, P, Redon, J, Verdecchia, P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27 (2009), 1360–1369.
12. 12 Bangalore, S, Messerli, FH, Wun, CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 31 (2010), 2897–2908.
13. 13 Cooper-DeHoff, RM, Gong, Y, Handberg, EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304 (2010), 61–68.
14. 14 Mancia, G, Schumacher, H, Redon, J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 124 (2011), 1727–1736.
15. 15 Redon, J, Mancia, G, Sleight, P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 59 (2012), 74–83.
16. 16 Sim, JJ, Shi, J, Kovesdy, CP, Kalantar-Zadeh, K, Jacobsen, SJ, Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 64 (2014), 588–597.
17. 17 Xie, X, Atkins, E, Lv, J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
18. 18 Wright, JT Jr, Williamson, JD, Whelton, PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
19. 19 Messerli, FH, Panjrath, GS, The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?. J Am Coll Cardiol 54 (2009), 1827–1834.
20. 20 Steg, PG, Greenlaw, N, Tendera, M, et al., Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Investigators. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med 174 (2014), 1651–1659.
21. 21 Heinzl, H, Kaider, A, SAS Technical Report KB-1-96: manual for the SAS macro RCS (version 2.0). http://cemsiis.meduniwien.ac.at/kb/wf/software/statistische-software/rcs/ (accessed Aug 17, 2016).
22. 22 Ovbiagele, B, Diener, HC, Yusuf, S, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 306 (2011), 2137–2144.
23. 23 Boutitie, F, Gueyffier, F, Pocock, S, Fagard, R, Boissel, JP, INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 136 (2002), 438–448.
24. 24 Rothwell, PM, External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 365 (2005), 82–93.
25. 25 Schiffrin, EL, Calhoun, DA, Flack, JM, SPRINT proves that lower is better for nondiabetic high-risk patients, but at a Price. Am J Hypertens 29 (2016), 2–4.
26. 26 Mancia, G, Fagard, R, Narkiewicz, K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
27. 27 Filipovsky, J, Seidlerova, J, Kratochvil, Z, Karnosova, P, Hronova, M, Mayer, O Jr, Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press 25 (2016), 228–234.
28. 28 Lonn, EM, Bosch, J, Lopez-Jaramillo, P, et al. Blood-Pressure Lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
29. 29 Sundstrom, J, Arima, H, Woodward, M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384 (2014), 591–598.
30. 30 Hansson, L, Zanchetti, A, Carruthers, SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
31. 31 Egan, BM, Zhao, Y, Axon, RN, US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303 (2010), 2043–2050.